Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study

BÜHLMANN fCAL® ELISA Citation:

 Beswick, L. et al. Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study.  Journal of Crohn’s and Colitis. 2017 Nov 7. DOI: 10.1093/ecco-jcc/jjx146.  PMID:  29121178 .

Highlight from this Publication

“In ASUC, post-first dose IFX, early assessment of serum/faecal IFX, calprotectin and partial Mayo scores can accurate predict future remission and colectomy, thus potentially aid decision-making, i.e. accelerated IFX dosing or surgical planning if/when needed.”

Read Citation

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use.

Health Canada License: 80726

This citation describes applications that are outside of product claims (Intended use is: The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.)